Table 4.
Antimicrobial Susceptibility Pattern of GNB Isolated from Patients with Ear Infection at the UoGCSH from Jan 2013 to Dec 2018
Drug (Tested) | P. mirabilis | P. vulgaris | E. coli | P. aeruginosa | Citrobacter spps | K. pneumoniae | Other NLF G-ve Rods | Other LF G-ve Rods | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S | R | S | R | S | R | S | R | S | R | S | R | S | R | S | R | |||||
AMP (119) | 5 | 17 | 2 | 14 | 2 | 13 | 1 | 14 | 0 | 12 | 0 | 8 | 1 | 6 | 4 | 4 | ||||
AMX (44) | 4 | 5 | 1 | 6 | 0 | 2 | 0 | 5 | 0 | 3 | 3 | 0 | 3 | 2 | 3 | 1 | ||||
AUG (32) | 3 | 3 | 2 | 1 | 0 | 3 | 0 | 3 | 0 | 6 | 0 | 2 | 0 | 2 | 0 | 2 | ||||
CRO (95) | 13 | 6 | 9 | 2 | 11 | 2 | 11 | 1 | 6 | 3 | 3 | 1 | 4 | 2 | 6 | 2 | ||||
CTX (25) | 3 | 5 | 4 | 0 | 1 | 2 | 0 | 1 | 2 | 1 | - | - | 0 | 1 | - | - | ||||
CRX (22) | 4 | 1 | 2 | 2 | 2 | 0 | 0 | 3 | - | - | 1 | 1 | - | - | 2 | 0 | ||||
CIP (102) | 13 | 4 | 12 | 0 | 12 | 4 | 11 | 1 | 11 | 1 | 6 | 2 | 5 | 1 | 6 | 0 | ||||
NOR (52) | 8 | 0 | 8 | 3 | 5 | 2 | 5 | 0 | 2 | 1 | 4 | 0 | 4 | 0 | 3 | 2 | ||||
NAL (33) | 0 | 3 | 4 | 8 | 1 | 4 | 1 | 2 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 2 | ||||
GEN (120) | 17 | 8 | 14 | 4 | 12 | 3 | 13 | 2 | 8 | 4 | 5 | 1 | 2 | 4 | 5 | 1 | ||||
TOB (8) | 3 | 1 | - | - | - | - | - | - | 1 | 0 | 1 | 0 | - | - | - | - | ||||
AMK (6) | 0 | 1 | - | - | 1 | 0 | 1 | 0 | - | - | 1 | 0 | - | - | - | - | ||||
TET (77) | 2 | 11 | 1 | 10 | 3 | 10 | 1 | 11 | 2 | 6 | 1 | 1 | 0 | 7 | 1 | 3 | ||||
DOX (11) | - | - | 0 | 1 | 0 | 2 | - | - | 0 | 1 | - | - | 1 | 3 | 0 | 1 | ||||
CAF (79) | 8 | 2 | 2 | 14 | 1 | 7 | 2 | 8 | 3 | 4 | 3 | 2 | 3 | 3 | 3 | 1 | ||||
SXT (61) | 6 | 5 | 5 | 6 | 2 | 6 | 1 | 5 | 4 | 1 | 3 | 3 | 2 | 3 | 1 | 1 | ||||
CLI (10) | 0 | 1 | 3 | 2 | 0 | 2 | - | - | - | - | - | - | - | - | 0 | 2 | ||||
MER (6) | 0 | 2 | - | - | - | - | - | - | 1 | 0 | 1 | 0 | - | - | - | - | ||||
Overall DSP (%) | 89 (54.3) | 75 (45.7) | 69 (48.6) | 73 (51.4) | 53 (46.1) | 62 (53.9) | 47 (45.6) | 56 (54.4) | 42 (49.4) | 43 (50.6) | 33 (61.1) | 21 (38.9) | 26 (42.6) | 35 (57.4) | 34 (60.7) | 22 (39.3) | ||||
Drug (Tested) | Other Klebsiella spps | Other Proteus spps | Other Pseudomonas spps | Salmonella spps | H. influenzae | Total N (%) | ||||||||||||||
S | R | S | R | S | R | S | R | S | R | S | R | |||||||||
AMP (119) | 0 | 4 | 1 | 4 | 0 | 1 | 3 | 2 | 0 | 1 | 19(16 | 100 (84) | ||||||||
AMX (44) | 0 | 1 | 0 | 2 | 0 | 3 | - | - | - | - | 14 (31.8) | 30 (68.2) | ||||||||
AUG (32) | 2 | 1 | - | - | 0 | 1 | 1 | 0 | - | - | 8(25) | 24 (75) | ||||||||
CRO (95) | 2 | 0 | 3 | 1 | 1 | 1 | 2 | 1 | 2 | 0 | 73 (76.8) | 22 (23.2) | ||||||||
CTX (25) | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 14(56) | 11(44) | ||||||||
CRX (22) | - | - | 0 | 2 | 0 | 1 | 1 | 0 | - | - | 12 (54.5) | 10 (45.5) | ||||||||
CIP (102) | 2 | 0 | 4 | 1 | 2 | 0 | 2 | 1 | 1 | 0 | 87 (85.3) | 15 (14.7) | ||||||||
NOR (52) | 1 | 0 | 2 | 1 | - | - | 1 | 0 | - | - | 43 (82.7) | 9 (17.3) | ||||||||
NAL (33) | - | - | - | - | 2 | 0 | 1 | 0 | - | - | 13 (39.4) | 20 (60.6) | ||||||||
GEN (120) | 2 | 2 | 4 | 1 | 3 | 0 | 3 | 2 | - | - | 88 (73.3) | 32 (26.7) | ||||||||
TOB (8) | - | - | - | - | 2 | 0 | - | - | - | - | 7 (87.5) | 1 (12.5) | ||||||||
AMK (6) | - | - | - | - | 1 | 0 | - | - | - | - | 4 (66.7) | 2 (33.3) | ||||||||
TET (77) | 0 | 1 | 0 | 2 | 0 | 3 | 0 | 1 | - | - | 11 (14.3) | 66 (85.7) | ||||||||
DOX (11) | - | - | - | - | 0 | 2 | - | - | - | - | 1 (9.1) | 10 (90.9) | ||||||||
CAF (79) | 0 | 3 | 0 | 1 | 0 | 3 | 1 | 3 | 2 | 0 | 28 (35.4) | 51 (64.6) | ||||||||
SXT (61) | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 30 (49.2) | 31 (50.8) | ||||||||
CLI (10) | - | - | - | - | - | - | - | - | - | - | 3(30) | 7 (70) | ||||||||
MER (6) | - | - | - | - | 2 | 0 | - | - | - | - | 4 (66.7) | 2 (33.3) | ||||||||
Overall DSP (%) | 11 (45.8) | 13 (54.2) | 16 (51.6) | 15 (48.4) | 14 (46.7) | 16 (53.3) | 17 (63) | 10(37) | 8 (88.9) | 1 (11.1) | 459 (50.9) | 443 (49.1) |
Abbreviations: AMP, ampicillin; AMX, amoxicillin; AUG, augmentin; CRO, ceftriaxone; CTX, cefoxitin; CRX, cefuroxime; CIP, ciprofloxacin; NOR, norfloxacin; NAL, nalidixic-acid; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; TET, tetracycline; DOX, doxycycline; CAF, chloramphenicol; SXT, co-trimoxazole; CLI, clindamycin; MER, meropenem; NLF, non-lactose fermenter; LF, lactose fermenter; DSP, drug-susceptibility pattern.